Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Nucala (Mepolizumab)
2
Mechanism of Action
Nucala selectively binds to IL-5 to inhibit binding to its receptor on the eosinophil surface. This reduces the production and survival of eosionophils
References:
How Supplied
Nucala [package insert] Research Triangle Park, NC. GlaxoSmithKline
Prepared by: Ayonna Tolbert
University of Florida
PharmD Candidate 2016
Side Effects
Nucala is available as a 100 mg single dose vial.
Each vial contains a sterile, preservative-free, lyophilized powder for reconstitution.
Warnings and Precautions
Most common side effects include:
Headache, injection site reactions, fatigue and back pain
Interleukin-5 Antagonist Monoclonal Antibody
Indication
Do not use to treat acute bronchospasm
Herpes zoster infections have occurred in patients receiving NUCALA. Consider varicella vaccination if medically appropriate prior to starting therapy with NUCALA
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decrease corticosteroids gradually, if appropriate.
Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype
Dosage
Preparation and Administration
100mg subcutaneously every 4 weeks
*For all approved age groups
*No renal/hepatic adjustment currently recommended
1. Reconstitute Nucala with 1.2mL Sterile Water
2. Gently swirl vial for 10 seconds at 15 second intervals (Do not shake, may take up to 5 minutes to reconstitute)
3. Visually inspect for particulate matter. Solution should be a translucent clear, pale yellow or pale brown color.
4. Remove 1 mL of the reconstituted solution from the vial and administer subcutaneously into the upper arm, thigh, or abdomen
5. If not used immediately, store below 30°C (86°F), do not freeze and discard if not used within 8 hours